Pioneering Gene Editing for ALS: Advancing ABO-202 and a Pipeline of CNS-Directed Therapeutics
Time: 1:30 pm
day: Conference Day Two Track B PM
Details:
- Introducing Arbor’s gene editing platform and unique commitment to CNS and ALS
- Deep dive into ABO-202: AAV-delivered gene editing approach targeting STMN2 to restore protective neuronal function
- Preclinical data supporting progression of ABO-202 toward IND-enabling studies
- Future directions for Arbor’s gene editing programs in ALS
